This study aimed to investigate the gene and protein expression of key inflammasome mediators in venous blood and skin biopsy samples from Brazilian psoriatic patients treated at the Pedro Ernesto University Hospital (HUPE). Samples were collected from both psoriatic patients and healthy controls. Gene expression was evaluated using quantitative reverse transcription polymerase chain reaction (qRT‒PCR), while protein levels were assessed through immunohistochemistry and multiplex immunoassays. Compared with those from control individuals, blood and skin biopsy samples from psoriatic patients had significantly higher mRNA levels of nucleotide-binding domain leucine-rich repeat (NLR) family pyrin domain containing receptor 1 (NLRP1), caspase-1, interleukin-1β (IL-1β), and interleukin-18 (IL-18). Immunohistochemical analysis revealed elevated protein levels of NLRP1, caspase-1, IL-1β, and IL-18 in psoriatic skin biopsies. Multiplex immunoassays revealed increased plasma levels of interferon-γ (IFN-γ), IL-1β, interleukin-17 A (IL-17 A), and tumor necrosis factor-α (TNF-α) in psoriatic patients. A positive correlation was observed between NLRP1 expression, disease severity, and the protein levels of IL-1β and TNF-α. In conclusion, in Brazilian psoriatic patients treated at HUPE, both blood and skin biopsy samples show increased expression of the NLRP1 inflammasome and its downstream mediators. Furthermore, NLRP1 expression is positively correlated with disease severity and the release of T helper 1-type cytokines, highlighting its potential role in the pathogenesis and progression of psoriasis.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00403-025-04029-wDOI Listing

Publication Analysis

Top Keywords

psoriatic patients
24
brazilian psoriatic
12
disease severity
12
blood skin
12
skin biopsy
12
biopsy samples
12
protein levels
12
nlr family
8
family pyrin
8
pyrin domain
8

Similar Publications

From the Masterclasses in Dermatology 2024 Meeting: Updates in Psoriasis Treatments.

J Clin Aesthet Dermatol

February 2025

Ms. Romanelli and Dr. Gottlieb are with the Department of Dermatology and Department of Medicine, Division of Rheumatology at Icahn School of Medicine at Mount Sinai in New York, New York.

Psoriasis (PsO) is an immune-mediated, chronic inflammatory skin disease that significantly impairs quality of life. Its treatment landscape is rapidly evolving, providing better disease control. Here, we highlight updates in biologics, obtaining coverage for biologics under Medicare, the PsO-to-psoriatic arthritis (PsA) transition, and orally administered drugs, as presented at the 2024 Masterclass in Dermatology in Puerto Rico.

View Article and Find Full Text PDF

[Emerging therapies for inflammatory rheumatic diseases].

Rev Med Suisse

March 2025

Service de rhumatologie, Département de l'appareil locomoteur, Centre hospitalier universitaire vaudois, 1011 Lausanne.

Rheumatologists face daily challenges in managing inflammatory rheumatic diseases (rheumatoid arthritis, axial spondylarthritis, and psoriatic arthritis). Significant advancements in our therapeutic arsenal have occurred over the past decades. However, achieving remission remains an unattainable goal for many patients, highlighting the need for new treatment options.

View Article and Find Full Text PDF

The interleukin (IL)-17 family encompasses six structurally related pro-inflammatory cystine knot proteins, designated as IL-17A to IL-17F. Over the last decades, evidence has pointed to its role as a critical player in the development of inflammatory diseases such as psoriasis (PsO), axial spondyloarthritis (axSpA), and psoriatic arthritis (PsA). More specifically, IL-17A and IL-17F are overexpressed in the skin and synovial tissues of patients with these diseases, and recent studies suggest their involvement in promoting inflammation and tissue damage in axSpA and PsA.

View Article and Find Full Text PDF

Delineating inflammatory from non-inflammatory mechanisms for therapy optimization in psoriatic arthritis.

Nat Rev Rheumatol

March 2025

Section of Musculoskeletal Disease, NIHR Leeds Musculoskeletal Biomedical Research Centre, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds, UK.

Psoriatic arthritis (PsA) is anatomically much more heterogeneous than rheumatoid arthritis, as, beyond synovitis, it often also involves enthesitis, peritendinitis, tenosynovitis, osteitis and periostitis. This heterogeneity currently precludes a gold standard for objectively defining resolution of inflammation following treatment, with enthesitis posing a particular challenge. Despite these difficulties, we apply lessons learned from rheumatoid arthritis to describe how patients with PsA and an inadequate response to therapy can be designated within two patient subgroups, characterized by persistent inflammatory PsA (PIPsA) and non-inflammatory PsA (NIPsA), respectively.

View Article and Find Full Text PDF

Introduction: Long-term treatment of psoriatic arthritis (PsA) is required to prevent progression. However, persistence with current treatments is challenging due to tolerability and acceptability issues. The objective of this study was to estimate 1-year persistence with secukinumab in patients with PsA treated with secukinumab, to compare persistence rates between secukinumab and adalimumab, to estimate usefulness rates, and to document adverse events.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!